Scinovex
review Open AccessTop 1% cited

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT)

Annals of the Rheumatic Diseases · 2006 · Vol. 65(10) · pp. 1312–1324
Weiya ZhangM DohertyT BardinE PascualV BarskovaP ConaghanJ GersterJ JacobsB LeebF LiotéG McCarthyP NetterG NukiF Perez-RuizA PignoneJ PimentãoL PunziE RoddyT UhligI Zimmermann-Gòrska
Gout, Hyperuricemia, Uric AcidUrticaria and Related ConditionsVenous Thromboembolism Diagnosis and ManagementMedicineGoutAllopurinolFebuxostatOdds ratioUricosuricBenzbromaronePhysical therapyInternal medicineIntensive care medicine

MeSH terms

Acute DiseaseDelphi TechniqueGoutGout SuppressantsHumansLife StyleRisk FactorsTreatment OutcomeEvidence-Based MedicineHyperuricemia

Funding

  • European League Against Rheumatism
Citations
1,414
FWCI
29.98
field-weighted impact
References
176
Percentile
100%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT) · Scinovex